Skip to main content
Journal cover image

Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories: The SPARCL Trial.

Publication ,  Journal Article
Szarek, M; Amarenco, P; Callahan, A; DeMicco, D; Fayyad, R; Goldstein, LB; Laskey, R; Sillesen, H; Welch, KM; SPARCL Committees and Investigators,
Published in: J Am Coll Cardiol
May 5, 2020

BACKGROUND: In the SPARCL (Stroke Prevention by Aggressive Reduction in Cholesterol Levels) trial, atorvastatin was compared with placebo in 4,731 participants with recent stroke or transient ischemic attack and no known coronary heart disease. Atorvastatin reduced the first occurrence of stroke and the first occurrence of a composite of vascular events. OBJECTIVES: The aim of this post hoc analysis was to assess the occurrence of all (first and subsequent) vascular events and the effect of atorvastatin to reduce these events by vascular territory (cerebrovascular, coronary, or peripheral) in SPARCL. METHODS: Treatment effects on total adjudicated vascular events, overall and by vascular territory, were summarized by marginal proportional hazards models. Vascular event rates were estimated for each treatment group with cumulative incidence functions. RESULTS: The placebo group had an estimated 41.2 first and 62.7 total vascular events per 100 participants over 6 years. There were 164 fewer first and 390 fewer total vascular events in the atorvastatin group (total events hazard ratio: 0.68; 95% confidence interval: 0.60 to 0.77). The total events reduction included 177 fewer cerebrovascular, 170 fewer coronary, and 43 fewer peripheral events. Over 6 years, an estimated 20 vascular events per 100 participants were avoided with atorvastatin treatment. CONCLUSIONS: In participants with recent stroke or transient ischemic attack, the total number of vascular events prevented with atorvastatin was more than twice the number of first events prevented. Total event reduction provides a comprehensive metric to capture the totality of atorvastatin clinical efficacy in reducing disease burden after stroke or transient ischemic attack. (Lipitor in the Prevention of Stroke, for Patients Who Have Had a Previous Stroke [SPARCL]; NCT00147602).

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Am Coll Cardiol

DOI

EISSN

1558-3597

Publication Date

May 5, 2020

Volume

75

Issue

17

Start / End Page

2110 / 2118

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Stroke
  • Male
  • Ischemic Attack, Transient
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Humans
  • Follow-Up Studies
  • Female
  • Cholesterol, LDL
  • Cardiovascular System & Hematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Szarek, M., Amarenco, P., Callahan, A., DeMicco, D., Fayyad, R., Goldstein, L. B., … SPARCL Committees and Investigators, . (2020). Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories: The SPARCL Trial. J Am Coll Cardiol, 75(17), 2110–2118. https://doi.org/10.1016/j.jacc.2020.03.015
Szarek, Michael, Pierre Amarenco, Alfred Callahan, David DeMicco, Rana Fayyad, Larry B. Goldstein, Rachel Laskey, Henrik Sillesen, K Michael Welch, and K Michael SPARCL Committees and Investigators. “Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories: The SPARCL Trial.J Am Coll Cardiol 75, no. 17 (May 5, 2020): 2110–18. https://doi.org/10.1016/j.jacc.2020.03.015.
Szarek M, Amarenco P, Callahan A, DeMicco D, Fayyad R, Goldstein LB, et al. Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories: The SPARCL Trial. J Am Coll Cardiol. 2020 May 5;75(17):2110–8.
Szarek, Michael, et al. “Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories: The SPARCL Trial.J Am Coll Cardiol, vol. 75, no. 17, May 2020, pp. 2110–18. Pubmed, doi:10.1016/j.jacc.2020.03.015.
Szarek M, Amarenco P, Callahan A, DeMicco D, Fayyad R, Goldstein LB, Laskey R, Sillesen H, Welch KM, SPARCL Committees and Investigators. Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories: The SPARCL Trial. J Am Coll Cardiol. 2020 May 5;75(17):2110–2118.
Journal cover image

Published In

J Am Coll Cardiol

DOI

EISSN

1558-3597

Publication Date

May 5, 2020

Volume

75

Issue

17

Start / End Page

2110 / 2118

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Stroke
  • Male
  • Ischemic Attack, Transient
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Humans
  • Follow-Up Studies
  • Female
  • Cholesterol, LDL
  • Cardiovascular System & Hematology